Published :
Tables : 62
Figures : 52
Category : Healthcare
No. of Pages : 230
Report Code : HC-U3338
Real-World Evidence Solutions Market is poised to value over USD 3 billion by 2027 end with a CAGR of over 14.8% during the forecast period 2020 to 2027. Randomised Controlled Trial are used to obtain results over a small patient set in a highly contained environment in a short time and across clinical trial centres that are dispersed. The life science companies have cited the potential of real-world data which is why they are emphasizing on evaluating the cost efficiency of drugs in real time and understanding their effect on the quality of healthcare. To fulfil the rising needs of the healthcare industry, there is a surging insistence for real-world proofs that rely on patient data registered by the administrators and practitioners during daily course. The data is collected from different sources and are used for making decisions, developing drugs and devices, reducing costs, improvements in the coordination of care and post-market monitoring. Market Segmentation: By Component • Data Sets • Consulting/ Services By Application • Oncology • Cardiovascular Disease • Neurology • Immunology • Others By End User • Pharmaceutical and Biopharmaceutical Companies • Healthcare Payers • Healthcare Providers • Other End Users By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is divided into component, application, end user and region. The component segment is fragmented into data sets and consulting. The data sets segment is fragmented into disparate data sets and integrated data sets. The data sets segment is predicted to hold the largest real-world evidence solutions market share owing to an increase in the amount of medical data that is generated in hospitals, rising dependence of studies based on outcomes on the basis of real world data, increased insistence for regulatory providers and bodies and payer information pertaining to drug safety. The application segment is categorised into oncology, CVD, neurology, infection, drug development and regulatory. The drug development and approvals segment dominated the market, and this can be credited to surging demand of RWE and RWD to boost the drug development and discovery, rising investments made by the biopharma companies in research and development activities. The end user segment is fragmented into pharmaceutical and biopharma companies, healthcare payers, healthcare providers and other end users. The pharmaceutical and biopharma companies lead the market, and this can be credited to the rising importance of studies pertaining to RWE in drug approvals and development, increased emphasis in avoiding expensive drug recalls. Regional Analysis: The North America region is predicted to dominate the market and this can be credited to the availability of data sets that are real-world, rising emphasis on care based on values, increased expenditure on research and development by biopharma companies, increased focus on early device and drug approvals and development and a strong presence of key market players in the region. Furthermore, strict rules and regulation for approving drugs and bolstering policies of the government. Competitive Landscape: Some of the prominent players included are Anthem, Inc., Clinigen Group plc, Cognizant, IBM Corporation, ICON plc, IQVIA, Optum,Inc., Oracle Corporation, PAREXEL International Corporation, PerkinElmer Inc., Pharmaceutical Product Development LLC., SAS Institute Inc., Syneos Health. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global real-world evidence solutions market by component, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Randomised Controlled Trial are used to obtain results over a small patient set in a highly contained environment in a short time and across clinical trial centres that are dispersed. The life science companies have cited the potential of real-world data which is why they are emphasizing on evaluating the cost efficiency of drugs in real time and understanding their effect on the quality of healthcare. To fulfil the rising needs of the healthcare industry, there is a surging insistence for real-world proofs that rely on patient data registered by the administrators and practitioners during daily course. The data is collected from different sources and are used for making decisions, developing drugs and devices, reducing costs, improvements in the coordination of care and post-market monitoring.
Market Segmentation:
By Component • Data Sets • Consulting/ Services By Application • Oncology • Cardiovascular Disease • Neurology • Immunology • Others By End User • Pharmaceutical and Biopharmaceutical Companies • Healthcare Payers • Healthcare Providers • Other End Users By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is divided into component, application, end user and region. The component segment is fragmented into data sets and consulting. The data sets segment is fragmented into disparate data sets and integrated data sets. The data sets segment is predicted to hold the largest real-world evidence solutions market share owing to an increase in the amount of medical data that is generated in hospitals, rising dependence of studies based on outcomes on the basis of real world data, increased insistence for regulatory providers and bodies and payer information pertaining to drug safety. The application segment is categorised into oncology, CVD, neurology, infection, drug development and regulatory. The drug development and approvals segment dominated the market, and this can be credited to surging demand of RWE and RWD to boost the drug development and discovery, rising investments made by the biopharma companies in research and development activities. The end user segment is fragmented into pharmaceutical and biopharma companies, healthcare payers, healthcare providers and other end users. The pharmaceutical and biopharma companies lead the market, and this can be credited to the rising importance of studies pertaining to RWE in drug approvals and development, increased emphasis in avoiding expensive drug recalls.
Regional Analysis:
The North America region is predicted to dominate the market and this can be credited to the availability of data sets that are real-world, rising emphasis on care based on values, increased expenditure on research and development by biopharma companies, increased focus on early device and drug approvals and development and a strong presence of key market players in the region. Furthermore, strict rules and regulation for approving drugs and bolstering policies of the government.
Competitive Landscape:
Some of the prominent players included are Anthem, Inc., Clinigen Group plc, Cognizant, IBM Corporation, ICON plc, IQVIA, Optum,Inc., Oracle Corporation, PAREXEL International Corporation, PerkinElmer Inc., Pharmaceutical Product Development LLC., SAS Institute Inc., Syneos Health.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global real-world evidence solutions market by component, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Real World Evidence Solutions Market, By Component Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 7.1 Data Sets 7.1.1 Disparate Data Sets 7.1.1.1 EMR/HER/Clinical Data 7.1.1.2 Pharmacy Data 7.1.1.3 Product/Disease Registries 7.1.1.4 Claims and Billing Data 7.1.1.5 Other Data 7.1.2 Integrated Data Sets 7.2 Consulting/ Services 8. Real World Evidence Solutions Market, By Application Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 8.1 Oncology 8.2 Cardiovascular Disease 8.3 Neurology 8.4 Immunology 8.5 Others 9. Real World Evidence Solutions Market, By End User Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 9.1 Pharmaceutical and Biopharmaceutical Companies 9.2 Healthcare Payers 9.3 Healthcare Providers 9.4 Other End Users 10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019 10.2.1. U.S. 10.2.2. Canada 10.2.3. Mexico 10.2.4. Rest of North America 10.3 Market Size (USD Mn) Forecast for North America 2020-2027 11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027 12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5 Switzerland 12.2.6. Spain 12.2.7. Russia 12.2.8. Poland 12.2.9. Rest of Western Europe 12.3 Market Size (US$ Mn) Forecast for Europe 2020-2027 13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1 Introduction 13.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 13.2.1 Japan 13.2.2 China 13.2.3 Singapore 13.2.4 Korea 13.2.5 India 13.2.6 Australia and New Zealand 13.2.7 ASEAN 13.2.8 Rest of Asia Pacific 13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027 14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1 Introduction 14.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 14.2.1 UAE 14.2.2 South Africa 14.2.3 Egypt 14.2.4 Saudi Arabia 14.2.5 Rest of MEA 14.3 Market Size (US$ Mn) Forecast for MEA 2020-2027 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 15.1 Anthem, Inc. 15.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2 Clinigen Group plc 15.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3 Cognizant 15.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4 IBM Corporation 15.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 ICON plc 15.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 IQVIA 15.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7 Optum Inc. 15.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8 Oracle Corporation 15.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9 PAREXEL International Corporation 15.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10 PerkinElmer Inc. 15.10.1. Company Overview (HQ, Business Segments, Employee Strength) 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11 Pharmaceutical Product Development LLC 15.11.1. Company Overview (HQ, Business Segments, Employee Strength) 15.11.2. Product Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 15.12 SAS Institute Inc. 15.12.1. Company Overview (HQ, Business Segments, Employee Strength) 15.12.2. Product Portfolio 15.12.3. SWOT Analysis 15.12.4. Financial Overview 15.12.5. Strategic Overview 15.13 Syneos Health 15.13.1. Company Overview (HQ, Business Segments, Employee Strength) 15.13.2. Product Portfolio 15.13.3. SWOT Analysis 15.13.4. Financial Overview 15.13.5. Strategic Overview 16. Impact of COVID-19 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. Competitive Intelligence and Competitive Matrix 17.1 Competitive Intelligence 17.2 Competitive Matrix 18. Major Deals and Strategic Alliances Analysis 18.1 Joint ventures 18.2 Mergers and acquisitions 18.3 Licensing and partnerships 18.4 Technology Collaborations 18.5 Strategic Divestments 18.6 Market Entry Strategies 19. Relevant Case Studies and Latest News Updates 20. Research Sources and List of Primary Contacts of this Study 21. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics